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Human cancer cell lines are used as important model systems to study molecular mechanisms associated
with tumor growth, hereunder how genomic and biological heterogeneity found in primary tumors affect
cellular phenotypes.We reconstructedGenome scalemetabolicmodels (GEMs) for eleven cell lines based on
RNA-Seq data and validated the functionality of these models with data frommetabolite profiling.We used
cell line-specific GEMs to analyze the differences in the metabolism of cancer cell lines, and to explore the
heterogeneous expression of the metabolic subsystems. Furthermore, we predicted 85 antimetabolites that
can inhibit growth of, or even kill, any of the cell lines, while at the same time not being toxic for 83 different
healthy human cell types. 60 of these antimetabolites were found to inhibit growth in all cell lines. Finally, we
experimentally validated one of the predicted antimetabolites using two cell lines with different phenotypic
origins, and found that it is effective in inhibiting the growth of these cell lines. Using
immunohistochemistry, we also showed high or moderate expression levels of proteins targeted by the
validated antimetabolite. Identified anti-growth factors for inhibition of cell growth may provide leads for
the development of efficient cancer treatment strategies.
H
uman cancer cell lines are widely usedmodel systems for studying cellular mechanisms underlying cancer
by analyzing their perturbation-response patterns in simplified experimental conditions1. Cell lines are
derived from human tumors of diverse tissue origin, and have adapted to growth in vitro for prolonged
periods. Comparative analysis of cell lines in combination with system-wide profiling techniques may disclose
cross cell-type commonalities and variations of biological processes. This knowledge can be used for understand-
ing cancer metabolism, identifying anticancer drugs, in vitro evaluation of predicted drug targets and outlining
mechanisms of action of therapeutic agents2,3.
Advances in omics technology have enabled simultaneous measurement of molecular components interacting
within complex interconnected networks and hereby provided insights into cellular functions and phenotypic
states of the cells. However, analyzing genome-wide data and in particular gaining new biological knowledge, is a
nontrivial effort4. Reconstruction of genome scale metabolic models (GEMs) can assist in this by integrating
omics data inmultiple layers to understand the effects of local interactions in the context of the whole network5–7.
This makes GEMs a potential tool for analyzing omics data in health and disease states, and for identifying the
underlying cellular mechanisms in the occurrence of complex diseases. To date, several generic human GEMs
have been generated8–11 and these models have been employed for reconstruction of context-specific GEMs for
healthy and cancerous cell-types. GEMs have been developed for studying the metabolic alterations between
healthy and cancerous tissues12,13 as well as within cancerous tissues14. Moreover, personalized cancer GEMs has
been reconstructed and used to capture common and specific metabolic shifts across the cancer patients and to
identify selective anticancer drugs15.
Preserved proliferative signaling and avoidance of growth suppressors have been identified as hallmarks of
cancer16. Adapting the cellular metabolism (e.g. increased synthesis of nucleotides, lipids and proteins) to
accommodate tumor expansion is a critical feature of cancer, and has been leveraged for development of novel
anticancer drugs17,18. In the present study, we used the concept of antimetabolites, which are structural analogues
of endogenous metabolites. Antimetabolites subvert cellular processes by serving as inhibitors of all enzymes
OPEN
SUBJECT AREAS:
BIOCHEMICAL
NETWORKS
BIOCHEMICAL REACTION
NETWORKS
Received
4 September 2014
Accepted
29 December 2014
Published
2 February 2015
Correspondence and
requests for materials
should be addressed to
J.N. (nielsenj@
chalmers.se)
SCIENTIFIC REPORTS | 5 : 8183 | DOI: 10.1038/srep08183 1
involved inmetabolizing the associated endogeneousmetabolite, and
hereby dramatically affecting metabolic functions19,20. An important
characteristic of antimetabolites is their potential to simultaneously
inhibit multiple enzymes, and thereby reduce the growth of prolif-
erating cells more effectively21. Antimetabolites are among the most
common anticancer drugs since the discovery of aminopterin, an
effective drug in remission of leukemia. Examples of antimetabolites
are antifolates (e.g. Methotrexate), antipyrimidines (e.g. Cytarabine,
5-Fluorouracil) and antipurines (e.g. 6-Mercaptopurine).
In this study, we first followed a systematic approach and analyzed
the global mRNA expression pattern of the 20,314 protein coding
genes in eleven human cancer cell lines22. Secondly, we reconstructed
functional cell line-specific GEMs (CL-GEMs) for these eleven cell lines
using mRNA expression levels (RNA-Seq) together with our tINIT
(task-driven Integrative Network Inference for Tissue) algorithm15
and Human Metabolic Reaction database (HMR)211 (Figure 1A). We
included known metabolic functions of the cell lines during the recon-
struction process, and validated functionality of the models based on
metabolite consumption and release (CORE) profiles of the cancer cell
lines1. Thirdly, we compared CL-GEMs by using a statistical multi-
comparison method as well as here defined heterogeneity scale. We
also compared metabolic subsystems in the CL-GEMs based on the
distribution of mRNA expression patterns of associated genes across
the cell lines. Fourthly, we screened all metabolites in the HMR2 to
identify essential metabolites for the growth of cell lines and predicted
potential antimetabolites that can inhibit or kill their growth. We
defined essential metabolites as metabolites for which their analogues
(antimetabolites) may disrupt the metabolic network and lead to cell
death. Each antimetabolite was also evaluated for its in silico toxicity by
employing GEMs for 83 human healthy cell-types. Next, we experi-
mentally tested the effect of an L-carnitine analogue, one of the poten-
tial antimetabolite that was predicted to be effective on all cell lines.
Significant difference in proliferation of cultured cell lines in presence
or absence of selected analogue, confirmed our computational predic-
tion. Finally, we presented high or moderate protein staining level of
the CPT1A and CPT1B, which were targeted by the L-carnitine ana-
logue in cell lines using the antibodies generated in the Human Protein
Atlas (HPA).
Results
Transcriptomics data of Human Cancer Cell lines. RNA-Seq have
been employed to identify the tissue-specific expression of genes
across the major human tissues and combined with the antibody
based profiling of the same tissues23–27. Previously, we also
performed a comparative transcriptomics analysis based on the
quantitative RNA profiling of protein-coding genes across eleven
human cancer cell lines derived from distinct cellular phenotypes22.
Fragment per kilobase of exon model per million mapped read
(FPKM) values were calculated for each gene, and expression levels
were categorized into high (FPKM. 50), medium (FPKM. 20) and
low (FPKM . 1), and FPKM , 1 was used to define genes as not
detected. Based on this cut-off the number of protein coding genes
expressed ranged from 11,000 to 12,500 across the eleven cell lines.
Approximately 43% of the expressed genes for each cell line were
found in the category of high and medium RNA expression levels
and the average transcript abundance score in a log2 scale ranged
from 4.90 for the epidermoid carcinoma cell line (A-431) to 5.30 for
the metastatic breast adenocarcinoma cell line (MCF-7) (Figure 1B).
The transcript profiling of cell lines was used to study the cross-cell
line distribution of detected protein coding genes (Figure 1C). In total,
15,292 out of 20,314 protein coding genes were expressed in at least
one of the cell lines, from which nearly 58% (n 5 8836) were
commonly detectable transcripts shared by all cell lines and the
remaining 42% (n 5 6456) distributed in different combination of
cell lines, with the highest contribution of cell specific genes (n 5
1285). Through in-depth analysis of the data, we found that there is
a connection between the mRNA expression levels of detected genes
and their presence across cell lines.We found that genes detected in all
eleven cell lines had higher transcript expression level compared to cell
specific genes, with an average of 9 fold change (Supplementary
Dataset 1).
Reconstruction of GEMs for human cancer cell lines. A generic
genome-scale metabolic model of cancer has been developed to
capture the common metabolic functions between cancer types28. A
core of 197 highly expressed metabolic genes common to more than
90% of the cell lines in the NCI-60 cell lines database have been
employed to reconstruct a generic cancer metabolic network, and
the resulting model was used to predict anti-cancer drug targets28.
Here, we reconstructed CL-GEMs for eleven human cancer cell lines
based on cell line specific RNA-Seq data, HMR2 and our task-driven
reconstruction approach. Lists of 56 metabolic tasks that are known
to occur in all cell types were used during the reconstruction process.
These metabolic tasks can be categorized as processes for provision of
energy and redox, biosynthesis of metabolites, substrate utilization
and internal conversion processes (Supplementary Dataset 2).
Growth was also added as a metabolic task to ensure that the cells
can proliferate. The CL-GEMs were reconstructed such that the
models should be able to perform all the defined tasks and at the
same time maintain the consistency with the transcriptomics data.
The eleven CL-GEMs are presented in the Human Metabolic Atlas
portal (http://www.metabolicatlas.org/) in the Systems Biology Mark-
up Language format.
The resulting CL-GEMs contained 5,297 to 5,584 reactions assoc-
iated with 2,193 to 2,328 genes and involving 4,209 to 4,432 meta-
bolites (Table 1, Supplementary Dataset 3). In total 2,774 genes, 4,663
metabolites and 6,127 reactions were shared between all models from
which 64.8% (n 5 1798) of genes, 85.2% (n 5 3975) of metabolites
and 78.3% (n 5 4798) of reactions were present in all of the CL-
GEMs. We found 149 cell line-specific genes, 36 cell line-specific
metabolites and 124 cell line-specific reactions were distributed
betweenmodels, where models for hepatocellular carcinoma cell line
(Hep-G2), osteosarcoma cell line (U-2 OS), urinary bladder trans-
itional cell carcinoma cell line (RT-4) and colon adenocarcinoma cell
line (CACO-2) contained nearly 70% of all the cell line-specific genes
(Figure 2A). Pair wise comparison of the CL-GEMs revealed that
each model has an average of 353 genes, 272 metabolites and 517
reactions being different from other cell lines, whereas the Hep-G2
and glioblastoma cell line (U-251 MG) showed highest degree of
difference based on genes and reactions, respectively (Figure 2B,
Supplementary Dataset 4). We also analyzed the transcript express-
ion pattern of CL-GEMs and observed an average expression level of
34 to 58 FPKM for all genes incorporated into the metabolic models,
approximately 4 fold higher than the expression level of cell line-
specific genes (Supplementary Dataset 3), which shows that meta-
bolism represents a core function in the cell lines.
We used CORE metabolite profiles of cancer cell lines1 to validate
the functionality of four CL-GEMs (PC-3, A-549, MCF-7 and U-
251) that were common in both studies. Constraining and optim-
izing the CL-GEMs based on CORE profiles, we observed that all
models obtained a feasible solution with flux distribution consistent
with published experimental data (Supplementary Dataset 5).
Heterogeneity of CL-GEMs. Cancer cells reprogram their metabolic
network to support cell proliferation by synthesizing all the cellular
components and the required Gibbs free energy16. Despite the shared
ability of transformed cells to induce growth stimulating adaptations
towards uniformity of metabolism, significant marks of diversity and
complexity in metabolic signatures of neoplasms has been recognized
in recent years29,30. In order to understand the heterogeneity of
metabolic networks in cancer, we used the reconstructed CL-GEMs
and analyzed the transformability of models based on differences in
their constituent parameters: genes, metabolites and reaction. We
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 5 : 8183 | DOI: 10.1038/srep08183 2
calculated the average Hamming distance and defined a heterogeneity
scale, independent of model size and parameter type, for CL-GEMs
and compared them with the GEMs for 83 healthy cell-types (see
M&M). Throughout the comparison, healthy cell-types showed an
average heterogeneity degree of 0.85 for genes, 0.70 for metabolites
and 0.80 for reactions whereas cell lines showed an average
heterogeneity degree of 0.78 for genes, 0.69 for metabolites and
0.74 for reactions (Figure 3A). Higher heterogeneity degree of
genes compared to reactions indicates the preference of parameter
effect to dimension effect, considering the fact that the number of
Table 1 | The reactions, metabolites and genes included in the CL-GEMs
CL-GEMs GENES Reactions Reactions Carry Flux Metabolites
A-431 Epidermoid carcinoma cell line 2193 5297 2914 4245
A-549 Lung carcinoma cell line 2318 5574 3335 4382
CACO-2 Colon adenocarcinoma cell line 2271 5472 2955 4326
HEK 293 Embryonal kidney cell line 2287 5274 2856 4220
HeLa Cervical epithelial adenocarcinoma cell line 2267 5570 3340 4397
Hep-G2 Hepatocellular carcinoma cell line 2273 5646 3431 4432
MCF-7 Metastatic breast adenocarcinoma cell line 2243 5402 3153 4318
PC-3 Prostate adenocarcinoma cell line 2297 5431 3328 4263
RT-4 Urinary bladder transitional cell carcinoma cell line 2251 5584 3326 4407
U-2 OS Osteosarcoma cell line 2328 5452 3221 4333
U-251 MG Glioblastoma cell line 2194 5320 3292 4209
Figure 1 | Pipeline for prediction of anti-growth factors using CL-GEMs. (A) CL-GEMs were reconstructed by introducing RNA expression profile of
20,314 protein coding genes across eleven human cancer cell lines into the HMR2 using the tINIT algorithm. CL-GEMs were used to evaluate all
metabolites present in HMR2 and to identify potential anti-growth factors, which were followed by filtering the pool metabolites and analyzing in silico
toxicity of predicted targets. Finally, one of the potential anti-growth factors were validated experimentally. (B) Protein coding genes for each cell line
were categorized based on the transcript expression levels. Stacked bars represent different expression levels and filled circles shows the average FPKM
value in log2 scale. (C) Distribution of 15,292 detected genes across different combination of cell lines are shown. Area curve represents cumulative
number of genes through different combinations of cell lines, while bar plots shows the percentage of each combination together with corresponding
number of genes inside the bar. 8,836 (,58%) of all detected genes were shared by all cell lines and remaining 42% distributed between different
combinations, from which cell specific genes outnumbers the other combinations with 1,285 (,8%) of assigned genes.
www.nature.com/scientificreports
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reactions in each model was in average 2.4 fold more than the number
of genes (Supplementary Dataset 3). A fall in heterogeneity degree,
approximately 0.07 degree based on genes and reactions, comparing
healthy cell-types to cell lines revealed a tendency towards the
uniformity of metabolic networks in cell lines. However, a significant
transformation was not observed and the models maintained their
heterogeneity. Interestingly, the heterogeneity degree of CL-GEMs
based on metabolites was stable, in contrast to genes and reactions,
and this indicated the preserved capability of altered metabolic
networks to transform the metabolites similar to healthy cell-types.
We also checked the number of the flux carrying reactions in each
model (Table 1) and found that the models show higher heterogen-
eity based on the flux carrying reactions even though the number of
the reactions in the models decreased by ,2 fold (Figure 3B and
Supplementary Dataset 6). This analysis clearly demonstrated the
difference in the metabolism of the cancer cell lines.
Next, using the transcriptome expression profile of genes included
into the CL-GEMs, we investigated the global shifts between the cell
lines. Kruskal-Wallis one-way analysis of variance31 was employed to
compare the distribution of mRNA expression pattern between mod-
els and calculated P-value 5 0.0029 rejected the hypothesis of sim-
ilarity of distributions at significance level of a 5 0.01. Furthermore,
we performed pair wise comparisons of CL-GEMs using Fisher’s LSD
test32 with a confidence level of 0.05 (Supplementary Dataset 7). We
found that Hep-G2 is the cell line with highest rate of significant
difference compared to the other cell lines, and all models except
Lung carcinoma cell line (A-549) and CACO-2 cell lines had a sig-
nificant difference compared to the Hep-G2 model. The A-549 and
CACO-2 models were also significantly different from U-251 MG
and U-2 OS models.
Thus, comparing GEMs through constituent parameters (genes,
metabolites and reactions) and also using mRNA expression pattern
disclosed a considerable difference betweenmetabolic models for the
eleven cell lines. This indicated the necessity of developing fine-tuned
CL-GEMs to capture the metabolic alterations that are specific to
each cancer cell line.
Heterogeneous expression of metabolic subsystems. We analyzed
the differences in mRNA expression pattern of the individual
pathways across the eleven cell lines. We calculated the fraction of
cell lines in which each metabolic subsystem had an average high
transcript expression (H) and low transcript expression (L), and
transferred the results into the (H 2 L) and (H 1 L) coordinates to
observe the behavior of subsystems across cell lines (Figure 4A). We
found highly, lowly and heterogeneously expressed subsystems in all
eleven cell lines, and this allowed us to focus on subsystems that can be
used for identifying generic or cell line-specific targets. As expected,
biosynthesis pathways that are essential for biomass production and
cell division displayed high expression levels in most of the cell lines,
from which fatty acid biosynthesis, b-oxidation of fatty acids and
cholesterol biosynthesis had the highest fraction of the H. Along
with these pathways, ROS detoxification, folate metabolism and
aminoacyl-tRNA biosynthesis displayed frequent high expression
pattern in many of cell lines.
In contrast, lipoic acid metabolism and glucocorticoid biosynthesis
revealed a relatively high fraction of L across all cell lines, which
followed by retinol metabolism and androgen metabolism. Lipoic
acid has been shown to reduce the proliferation/viability and to
increase apoptosis of tumor cells33. Moreover, it has been reported
that deficiency of lipoic acid synthetase results in defected mitochon-
drial energy metabolism and glycine cleavage mechanism as reflected
by lactic acidosis and elevation of glycine34,35. Glucocorticoids have
been used to treat wide range of cancers based on their substantial
effect on progression of cell cycle and apoptosis through glucocorti-
coid receptor mediated mechanisms36–38. Retinoids are used for can-
cer treatment because of their ability to promote cell differentiation
and also to change the gene expression pattern of tumor cells making
them more vulnerable to other therapies39–41.
Figure 2 | Differences between the CL-GEMs. (A) Distribution of cell specific genes, metabolites and reactions across CL-GEMs (bar plots). Filled circles
represent average Hamming distance of each CL-GEM compared to other models. Here, Hamming distance is an indicator of required change to
transform one model to the other based on each parameter (Supplementary Dataset 4). For example, 363 changes in genes profiles are required for inter-
transformation of metastatic breast adenocarcinoma cell line (MCF-7) and glioblastoma cell line (U-251 MG), from which 206 changes in genes
corresponds to transformation of MCF-7 to U-251 MG and 157 changes in genes corresponds to transformation of U-251 MG to MCF-7. (B) Pair wise
comparison of CL-GEMs based on genes and reactions. Numbers inside the colored squares represent the ratio of pair wise difference between CL-GEMS
compared to maximum observed difference across all models.
www.nature.com/scientificreports
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Wenext studied the inter-cell expressional variation of subsystems
to explore the heterogeneous behavior of metabolic pathways across
the different cell lines. Bile acid recycling, fatty acid desaturation,
ascorbate and aldarate metabolism, formation and hydrolysis of cho-
lesterol esters, and vitamin D metabolism showed higher heterogen-
eity among all subsystems in HMR2 (Figure 4B). In CACO-2,
cervical epithelial adenocarcinoma cell line (HeLa) and Hep-G2,
genes involved in bile acid recycling pathway mainly had low
mRNA expression level, whereas in A-431 and RT-4, these genes
had high expression levels. Almost all genes associated with reactions
in fatty acid desaturation pathways were highly expressed in CACO-
2 and Hep-G2 without showing a considerable high or low express-
Figure 3 | The heterogeneity of healthy cell-types and human cancer cell lines. (A) Heterogeneity degrees of GEMs for 83 healthy cell-types and cancer cell
lines are projected on the left hand side axis. There is a relatively low, 0.07 degree, tendency towards uniformity ofmetabolic networks in cell lines comparing
to healthy cell-types. Both GEMs for healthy cell-types and cancer cell lines show higher heterogeneity for genes and reactions compared to metabolites.
However, the heterogeneity of models based on metabolites is stable, in contrast to reactions and genes. Hamming distances of GEMs for 83 healthy cell-
types and CL-GEMs are projected on the right hand side axis. There is relatively high, ,50%, fall in Hamming distance for cell lines compared to healthy
cell-types as result of tremendous dimensional variations, ,4 fold change, in metabolic models of healthy cell-types. In general, models show higher
heterogeneity based on genes and larger distance based on reactions. (B) Heterogeneity of flux carrying as well as all reactions in CL-GEMs is shown on the
left hand side axis. Hamming distances of CL-GEMs with flux carrying and all reactions are projected on the right hand side axis. Even though the content of
the models decreased after removal of non-flux carrying reactions, the heterogeneity of the models was slightly increased.
www.nature.com/scientificreports
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ion pattern for other cell lines. Formation and hydrolysis of choles-
terol esters pathway was completely dominated by highly expressed
genes for A-431 and A-549 different from other cell lines. Vitamin D
metabolism revealed a different genes expression pattern for U-251
MG with low transcript level for all associated genes which followed
by RT-4 and embryonal kidney cell line (HEK 293) with more than
70% of genes with low expression level. These analyses suggested that
the activities of heterogeneous pathways are not influenced only by
variability of environmental conditions, but also by the specific gen-
etic repertoire of each individual cell line.
Anti-growth Factors for Cell Lines. We used reconstructed CL-
GEMs to predict the potential antigrowth factors through analyzing
the robustness of metabolic networks against the induced pertur-
bations. The metabolite-centric approach based on the concept of
antimetabolites was employed to introduce the growth inhibiting
perturbations. By testing the essentiality of metabolites present in the
HMR2 on growth of cancer cell lines, we predicted 138 antimetabolites
that can kill the growth on any of eleven studied cell lines and 106 of
them were found to be effective in all cell lines. However, using these
antimetabolites for the treatment of the cancer may have toxic effects to
healthy cell-types in the human body. Therefore, we performed in silico
toxicity test using the previously published GEMs for 83 different cell
types in the human body. We checked if the use of the antimetabolites
would potentially disrupt the metabolic tasks in energy production.
We finally predicted 85 potential antimetabolites that can inhibit
growth of any cell lines studied here, while not being toxic to healthy
cells (Supplementary Dataset 8). We found that 70.6% (n 5 60) were
effective in all cell lines, 11.8% (n5 10)were effective in two cell lines,
17.6% (n 5 15) were effective in just one cell line, and interestingly
not any antimetabolite was detected for 3 to 10 combinations of cell
lines (Supplementary Dataset 9). Although,70% of antimetabolites
were predicted to be effective in all cell lines, the fact that 30% were
cell-line specific indicated the importance of using cell line specific
models rather than depending on one generic cancer model.
Furthermore, we categorized 85 predicted antimetabolites based
on their relevant subsystems in HMR2 and calculated the average
mRNAexpression level of the subsystems across cell lines (Figure 5A,
Supplementary Dataset 10). It was observed that nucleotide meta-
bolism, amino acids metabolism and cholesterol biosynthesis con-
tain the highest fraction of antimetabolites, more than 68%. This was
followed by sphingolipid, glycerophospholipid and folate metabol-
ism. In general, pathways containing higher fraction of predicted
antimetabolites showed high average mRNA expression levels in
all cell lines and the exceptions were closely connected to one or
more pathways with high average expression levels. For example,
the carnitine shuttle had relatively low average expression level,
but deficiency in this pathway results in deficiency of the b-oxidation
pathway that has one of highest average RNA expression levels
within all cell lines.
Following the prediction of L-carnitine as an antimetabolite and
considering the connection of the L-carnitine shuttle to the mito-
chondrial b-oxidation, the analogue of L-carnitine were proposed as
a potential antigrowth factor targeting the growth in all eleven cell
lines (Figure 5B). L-carnitine is an essential metabolite that plays an
important role in fatty acids metabolism and energy production. In
humans, carnitine homoeostasis is preserved by dietary absorption
and also through a multi-step de novo biosynthesis42. L-carnitine can
be synthesized in liver and kidney using essential amino acids lysine
and methionine as primary precursors to form trimethyllysine
(TML)43,44. Notably, both lysine and methionine were also detected
as antimetabolites through our analysis.
b-Oxidation was found to have high average mRNA expression
levels in all eleven cell lines. This pathway consists of recurrent series
of reactions that result in cyclical shortening of fatty acids and pro-
duction of acetyl CoA, NADH and FADH. Generated NADH and
Figure 4 | Metabolic subsystems in CL-GEMs. (A) Transcriptome expression pattern ofmetabolic subsystems in CL-GEMs are demonstrated.Metabolic
subsystems are shown inH2 L andH1 L coordinates, whereH is the fraction ofmodels in which a subsystem has average high RNA expression level, and
L is the fraction of models in which a subsystem has average low RNA expression level. Subsystems with dominantly high expression pattern clustered on
the upper right corner of the plot, whereas subsystems with dominantly lower expression pattern occupy position in the upper left corner. Subsystems
with heterogeneous behavior across cell lines are placed in the upper middle near zero on horizontal axis. Red dashed lines shows 40% of horizontal
expansion and the blue dashed lines represent 20% of horizontal deviation. (B) Inter-cell line variation of heterogeneity in metabolic subsystems are
demonstrated. Subsystems are shown in SH2 SL and SH1 SL coordinates, where for each pathway SH is the standard deviation of high RNA expression
level across cell lines, and LH is the standard deviation of low RNA expression level. Subsystems withmore variation in high RNA expression level occupy
positions in the right-hand side of zero on horizontal axis, whereas subsystems withmore variation in lowRNA expression level placed in left-hand side of
zero on horizontal axis. Subsystems with less expressional variation across cell lines are clustered in the lower part of the plot near zero on the horizontal
axis. Heterogeneity mainly happens in the upper and upper right areas within the plot which are marked with dashed lines.
www.nature.com/scientificreports
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FADH are used for ATP production through electron transport
chain, while acetyl CoA enters the citric acid cycle (TCA)44–46.
Carnitine shuttle acts as the carrier for the long chain fatty acid acyl
groups and transports them from the cytosol to the mitochondria,
where b-oxidation occurs. L-carnitine has an important role in trans-
fer of the acetyl-CoA produced by peroxisomal b-oxidation to the
mitochondria for oxidation. Other functions performed by L-carni-
tine include storing energy as acetylcarnitine, regulating the ratio of
acyl-CoA to CoA and exerting the poorly metabolized acyl groups as
carnitine esters to adjust their toxic effects42–44,47,48.
The use of L-carnitine analog inhibits the carnitine palmitoyl-
transferase (CPT) 1 and 2 enzymes that catalyze the L-carnitine
and fatty acyl CoAs. We used perhexiline malate salt (perhexiline)
that inhibits CPT1 and partly CPT2 to mimic the effect of the poten-
tial L-carnitine antimetabolite. To confirm our prediction about the
use of L-carnitine analogue as potential antigrowth factor for all cell
lines, we tested the effect of Perhexiline on the proliferation of pro-
state carcinoma cell line (PC-3) and A-431. Perhexiline was used to
imitate the L-carnitine mechanism of effect since mitochondrial
enzyme CPT1, as a member of carnitine acyltransferases family of
enzymes, is responsible for translocation of conjugated L-carnitine
and long chain FAs from cytosol to the mitochondria (Figure 5B).
We treated two cell lines with four different concentrations of
Perhexiline (2, 4, 8 and 24 mM) and investigated the viability of cells
after 24 and 48 hours with eight replicates (Figure 6A–B). For lower
concentration of Perhexiline (4 and 6 mM), we repeated our experi-
ments with 16 replicates for 48 hours (Figure 6C–D). Significant
reduction (t-test, p-value 0.05) in cell lines viability was observed
with Perhexiline concentrations more than 2 mM for PC-3 and
4 mM for A-431.
We also analyzed protein expression level of CPT1 and CPT2
using the antibodies generated in the HPA project49 and observed
that CPT1 and CPT2 had strong or moderate protein expression
levels. Protein expression levels as detected by using immunoshisto-
chemistry are exemplified in a subset of cell lines in Figure 7.
Discussion
Recent advances in understanding cancer cell biology and continu-
ous development of high throughput analytical methods have
revealed that cancer is remarkably complex and heterogeneous.
Increased understanding of this genomic heterogeneity between dif-
ferent tumorsmay open a newwindow towards the development and
optimization of therapeutic methods for specific cancer types. GEMs
provide amechanistic description of relationships between genes and
metabolic functions, and they can therefore be used for the inter-
pretation of large experimental datasets. In this study we recon-
structed CL-GEMs for eleven human cancer cell lines based on
RNA expression data and used the generated models to understand
the heterogeneity of metabolic networks in cancer cell lines. Our
analysis revealed notable heterogeneity across CL-GEMs, where each
Figure 5 | Prediction of antimetabolites through the use of CL-GEMs. (A) Distribution of 85 predicted antimetabolites and their corresponding
metabolic subsystems in HMR2 are presented. Color gradient shows the average RNA expression level of related pathways in log2 scale. Stars indicate the
two pathways with highest and lowest expression levels. (B) L-carnitine was predicted as an essential metabolite, and the use of its analogue was proposed
for inhibiting the growth in all eleven cell lines. The predicted mechanism of action of an L-carnitine analogue is presented. L-carnitine antimetabolite
may reduce b-oxidation and de novo fatty acids synthesis which is required for synthesis of the cell membrane and for cell proliferation. The abbreviations
and the detailed explanations for the metabolites as well as the associated genes for each reaction are presented in HMR2.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 5 : 8183 | DOI: 10.1038/srep08183 7
model had an average of 353 different genes (heterogeneity degree of
0.78), 272 different metabolites (heterogeneity degree of 0.69) and
517 different reactions (heterogeneity degree of 0.74) in comparison
to other models. Comparing CL-GEMs with GEMs for 83 healthy
cell-types, we found a slight tendency towards the uniformity of
metabolic networks in CL-GEMs and the heterogeneity of models
preserved to a large extent. This finding indicates inadequacy of
reconstructing a generic cancer model to capture metabolic altera-
tions in transformed cells.
We analyzed the RNA expression pattern of individual pathways to
identify the transcriptome based distribution of subsystems across
CL-GEMs. We found that genes involved in fatty acid biosynthesis
and cholesterol biosynthesis had highest average mRNA expression
level in most of the cell lines, which shows the importance of biosyn-
thesis pathways in transformed cells. On the other hand, lipoic acid
metabolism and glucocorticoid biosynthesis revealed lowest average
expression level among subsystems consistent with previously pub-
lished studies indicating their positive correlation to reduced cell
proliferation/viability and increased apoptosis of tumor cells33.
Through in-depth analysis of expressional variation of subsystems
across CL-GEMs, we found that bile acid recycling, fatty acid desa-
turation, ascorbate and aldarate metabolism, formation and hydro-
lysis of cholesterol esters, and vitamin Dmetabolism are the pathways
with highest expressional heterogeneity among all subsystems in
HMR2. Subsystems with high expressional variation may be potential
targets for further studies to find cell line specific targets.
Metabolite essentiality, defined as metabolites necessary for cell
growth and survivor, has previously been used50 to identify potential
drug targets for an opportunistic pathogen using GEMs. We used
this concept to explore essentialmetabolites in CL-GEMs by perturb-
ing the metabolic networks and found metabolites contributing to
growth inhibiting perturbations. The structural analogues of 85 pre-
dicted essential metabolites, which passed the in silico toxicity test
based on previously generated GEMs for 83 healthy human cell
types, proposed as potential antimetabolites. Analogues of L-carni-
tine were proposed as potential antimetabolites, due to their key role
in L-carnitine shuttle pathway, and the contribution of L-carnitine
shuttle to the mitochondrial b-oxidation and consequently to the
fatty acid synthesis. Two cell lines with different phenotypic origins,
PC-3 and A-431 were selected for in vitro testing of our prediction
Figure 6 | Inhibitory effect of Perhexiline on the proliferation of cell lines. Effect of Perhexiline on the proliferation of prostate carcinoma cell line, PC-3
and epidermoid carcinoma cell line, A-431 are shown. Perhexiline was used tomimic the L-carnitine analoguemechanism of effect on the proliferation of
PC-3 and A-431 cell lines. (A) PC-3 and (B) A-431 cell lines were treated by 2, 4, 8 and 20 mMof Perhexiline and viability of cells determined after 24 and
48 hours. Perhexiline was dissolved in DMSO, and corresponding concentrations of DMSO in the medium were used as controls. Results of analyzing
eight replicates of all concentrations and corresponding controls were represented by bar plots, mean 6 standard deviation. Significantly difference
between control and treated cell line: * (Student’s t-test, p-value, 0.05). (C) PC-3 and (D) A-431 cell lines were treated by 4 and 6 mMof Perhexiline and
viability of cells determined after 48 hours. Results of analyzing 16 replicates of two concentrations and corresponding controls were represented by bar
plots, mean 6 standard deviation. Significantly difference between control and treated cell line: * (Student’s t-test, p-value , 0.05).
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using Perhexiline to mimic the effect of L-carnitine analogue. Both
cell lines revealed significant reduction in cells viability in presence of
Perhexiline, validating the relevancy of predicted target. The effect of
Perhexiline on viability of Hep-G2 has previously been verified by
ref. 15, and is consistent with our findings.
Plasticity is one of the key factors to maintain fitness of trans-
formed cells and b-oxidation of fatty acids may prepare some of this
plasticity by supplying metabolic intermediates for cell proliferation,
suppressing pro-apoptotic subsystems, eradicating potentially cyto-
toxic lipids, and empowering the production of NADPH and ATP
when required51–55. However, b-oxidation of fatty acids cannot be
discerned as an independent metabolic pathway in cancer metabol-
ism and there is a challenge to unify the essential role of b-oxidation
pathway in tumor cells with the fact that active fatty acid synthesis is
necessary for cancer cells division and proliferation.
Despite promising performance of GEMs in identification of bio-
markers and drug targets for cancer, there are cautions and limita-
tions regarding this approach. Unlike bacteria, reconstructing and
testing the functionality of GEMs is more complex when it comes to
cells and tissues. Constructing new generation of unified GEMs that
integrate metabolism with other cellular processes, especially signal-
ing and regulation, remains as a nontrivial challenge. Different
assumptions to estimate the connection between transcription,
translation and flux rate challenges the accuracy and compatibility
of models generated by incorporating omics data into GEMs.
In conclusion, we used CL-GEMs to investigate the differences in
the metabolism of cell lines and explore potential antigrowth factors,
which may impede the growth of cancer cells, and experimentally
verified the inhibitory effect of the L-carnitine analogue, one of the
predicted antimetabolite. The study of cancer metabolism using
GEMs has revealed new therapeutic opportunities, as well as more
profound understanding of metabolic reprogramming of cancer
cells. Over the past decades we learned that targeting single pathways
or enzymes is not enough to cure cancer and agents proposed here as
antigrowth factors may be combined with other therapeutic agents
andmethods to get desired results. The approach presented heremay
also be extended to study the combinatory effect of potential and
standard therapeutic agents to find more effective cancer specific
therapies, and may present new possibilities towards personalized
medicine.
Methods
GEM reconstruction. The tINIT algorithm15 implemented in the RAVEN toolbox56
was used for the reconstruction of eleven CL-GEMs. 56Metabolic functions known to
occur in all cell lines as well as growth were used during the reconstruction process of
the GEMs (Supplementary Dataset 2). During the reconstruction of the model, we
used the content of Ham’s media as minimal media required for cell growth. The
content of the Ham’s media is provided in Supplementary dataset 2.
Heterogeneity of CL-GEMs. A new measure of heterogeneity was used in our study
to capture the divergence between metabolic networks based on their constituent
parameters: genes, reactions and metabolites. For each model, heterogeneity degree
formulated as:
dhi j~
log2 hi j
 
log2 Hi j
  i~1 . . . n, j~1 . . . m ð1Þ
Where dhij is the heterogeneity degree of model i based on parameter j, hi j is the
average Hamming distance of model i to all other models based on parameter j,Hi j is
maximum Hamming distance of model i based on parameter j in comparison to
integrated vector of parameter j (Ivj). In this formulation, n is the number of models
(83 for healthy cell-types and 11 for cancer cell lines), m is the number of the
constituent parameters (here parameter are genes, reaction and metabolites, m 5 3),
and Ivj is a unique union of corresponding parameter across all models. For example,
I.v1 represent a union vector of genes present at least in one of the models.
To compare the CL-GEMs based on RNA expression levels, we built a vector of
expected transcriptome expression values of genes linked tometabolic subsystems for
each model, and merged these vectors into n 3 m unified ratio matrix. Here, n is
number of subsystems and m is the number of the models. We used this matrix to
perform multi-comparison analysis employing Kruskal-Wallis non-parametric test
with significance level of 0.01. Finally, we performed pair wise analysis of models
using post hoc Fisher’s LSD test with confidence level of 0.05.
Heterogeneous expression of metabolic pathways. To identify the heterogeneous
expression of metabolic subsystems across the cell lines, we calculated the ratios of
high and low RNA expression level for genes associated to reactions inside the CL-
GEMs in logarithmic scale. For each pathway, we calculated the average ratio of high
expression level and low expression level and integrated the results into two different
n3m ratio matrices, highmatrix (HM) and lowmatrix (LM), respectively. Here, n is
number of pathways and m is the number of models. We used a subsystem-specific
metrics, HM-LM and HM 1 LM, to compare the expression pattern of pathways
across the cell lines.
In silico toxicity test. Inhibition of essential metabolites in cancer cell lines can also
disrupt the metabolism of healthy cells, similar to chemotherapeutic drugs. To avoid
this side effect, we used reconstructed GEMs for 83 healthy cell types and investigated
the response of thesemetabolic models against inhibition of essential metabolites.We
excluded the essential metabolites that disrupted energy metabolism and redox
balance in healthy cells. Our approach was based on the central role of energy
producing tasks for all cell types, and also high likelihood of neoplastic shifts in energy
metabolism of transformed cells.
Effect of Perhexiline on PC-3 and A-431 cell lines. A proliferation assay was
performed using the colorimetric CellTiter 96H AQueous One Solution Cell
Proliferation Assay (MTS) (Promega) on PC-3 and A-431 according to instructions
from the manufacturer (DSMZ, Braunscweig, Germany). In brief, the two cell lines
were treated with 2, 4, 8 and 20 mM of Perhexiline Malate salt (Sigma-Aldrich, St.
Louis, USA) for 24 and 48 hours respectively. Perhexiline was dissolved in DMSO,
and corresponding concentrations of DMSO in medium were used as controls. In
addition, controls consisting of cells growing in only cell culture medium were
included. For all concentrations and corresponding DMSO-controls eight replicates
were analysed, and for the controls consisting of cells in only medium 16 replicates
were analysed. In the follow up experiment the two cell lines were treated with 4 and
6 mM respectively of Perhexiline Malate salt (Sigma-Aldrich, St. Louis, USA) for
48 hours. This time 16 replicates were used for all conditions and controls.
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